Aaron Farberg, MD

An expert discusses how examining biosimilars in trials ensures safety, efficacy, and interchangeability, key for clinical adoption. The phase 3 study’s week 52 results confirmed consistent pharmacokinetics, efficacy, and safety. As confidence grows, biosimilars will expand treatment access for psoriasis patients.

An expert discusses how comparative studies of FDA-approved psoriasis biologics are crucial for treatment optimization. This study compared tildrakizumab with ustekinumab, analyzing discontinuation, persistence, adherence, and switching. Results showed favorable persistence and adherence. Provider administration may have influenced outcomes, impacting clinical decisions.

An expert discusses how the VISIBLE study examined comorbidity burden in moderate to severe psoriasis across all skin tones, addressing disparities in research. It aimed to highlight unmet needs and improve understanding of disease impact in diverse populations.

An expert discusses how health care provider administration may improve adherence to tildrakizumab. The meta-analysis confirms its real-world efficacy, safety, and quality of life benefits, supporting clinical use. These findings may influence payer decisions by reinforcing its value and long-term effectiveness in psoriasis care.

An expert discusses how the study assessed real-world effectiveness of tildrakizumab for moderate to severe plaque psoriasis, crucial for validating clinical trial results. Multisite data enhanced reliability, while a systematic review and meta-analysis confirmed efficacy, safety, and quality of life benefits, aligning with trial findings.